Benzinga · Oct 21, 2026
B. Riley Securities Reiterates Buy on MiNK Therapeutics, Raises Price Target to $50
B. Riley Securities analyst Mayank Mamtani reiterates MiNK Therapeutics (NASDAQ:INKT) with a Buy and raises the price target from $43 to $50.
IN
NASDAQ · INKT
MiNK Therapeutics, Inc.
Healthcare · Biotechnology
$10.53
Down-$0.35 (-3.17%)
Updated Nov 2, 2026, 9:48 AM
SID Score
3.0/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 58.3M
- P/E ratio
- -0.01
- Dividend yield
- 0.00%
- 52-week range
- $8.48 – $16.93
- Volume
- 8.68K
- Avg. volume
- 28.08K
Price performance · INKT
INKT price history
1M range · 20 trading sessions · Daily adjusted prices
Prices through Oct 30, 2026
INKT closed at $10.53 after 20 trading sessions, down 13.69% for the selected period.
- Last close
- $10.53
- Period change
- -13.69%
- Period low
- $9.41
- Period high
- $12.20
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 30, 2026 | $10.55 | $10.86 | $10.3501 | $10.53 | 8.68K |
| Oct 29, 2026 | $10.83 | $11.13 | $10.4051 | $10.875 | 9.69K |
| Oct 28, 2026 | $10.76 | $11.4499 | $10.76 | $10.80 | 6.13K |
| Oct 27, 2026 | $10.48 | $10.8466 | $10.4079 | $10.63 | 10.15K |
| Oct 26, 2026 | $10.75 | $11.40 | $10.43 | $10.43 | 13.32K |
| Oct 23, 2026 | $10.635 | $11.68 | $10.18 | $10.71 | 29.54K |
| Oct 22, 2026 | $10.65 | $10.65 | $10.06 | $10.06 | 9.83K |
| Oct 21, 2026 | $9.80 | $10.99 | $9.80 | $10.62 | 18.61K |
| Oct 20, 2026 | $9.31 | $9.97 | $9.19 | $9.86 | 8.44K |
| Oct 19, 2026 | $9.61 | $9.68 | $9.25 | $9.56 | 14.15K |
| Oct 16, 2026 | $9.87 | $10.10 | $9.38 | $9.41 | 13.63K |
| Oct 15, 2026 | $10.35 | $10.35 | $9.9337 | $9.94 | 10.1K |
| Oct 14, 2026 | $10.17 | $10.35 | $10.09 | $10.35 | 6.02K |
| Oct 13, 2026 | $10.44 | $10.65 | $10.12 | $10.23 | 7.17K |
| Oct 12, 2026 | $10.90 | $11.2357 | $10.36 | $10.53 | 18.78K |
| Oct 9, 2026 | $10.96 | $10.96 | $10.6801 | $10.72 | 16.98K |
| Oct 8, 2026 | $11.5627 | $11.5627 | $10.96 | $11.00 | 10.58K |
| Oct 7, 2026 | $11.63 | $11.63 | $11.32 | $11.42 | 13.81K |
| Oct 6, 2026 | $12.11 | $12.20 | $11.63 | $11.70 | 33.08K |
| Oct 5, 2026 | $12.51 | $12.8346 | $12.10 | $12.20 | 28.58K |
Latest INKT news
The latest Smart Investors Daily articles mentioning INKT.
Stock researchCompany · Overview
Company
Market Activity
Research & News
INKT research
Overview
Company profile and research snapshot.
Company profile
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company is advancing a pipeline of both native and next generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $35.00
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 21, 2026 | B. Riley Securities | Buy | — |
| May 18, 2026 | HC Wainwright & Co. | Buy | — |
| Apr 1, 2026 | HC Wainwright & Co. | Buy | — |
| Aug 15, 2025 | HC Wainwright & Co. | Buy | — |
| Jul 15, 2025 | HC Wainwright & Co. | Neutral | — |
News briefing
No generated briefing is available yet.
Yahoo · Oct 2, 2026
MiNK Therapeutics to Present Data on Treatment-Resistant Colorectal Cancer and Clearance of Senescent Tumor Cells and Fibroblasts at SITC 2026
agenT-797 enables tumor-cell killing in a human relevant model of checkpoint inhibitor–resistant colorectal cancer liver metastasesNative and engineered iNKT cells eliminate senescent tumor cells and fibroblasts in preclinical models, supporting complementary approaches to cancer treatment NEW YORK, Oct. 02, 2026 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic invariant natural killer T (allo-iNKT) cell therapies to res
Yahoo · Sep 30, 2026
MiNK Therapeutics Selected for ARPA-H-Funded Initiative to Advance Room-Temperature Cell Therapy
Clinical-stage agenT-797 iNKT platform selected as therapeutic cell platform for ARPA-H BoSS program aimed at taking living medicines from cryogenic storage toward room temperature ARPA-H has committed up to $87 million across the four-year BoSS program to reduce cold-chain dependence and expand access to cell-based medicines NEW YORK, Sept. 30, 2026 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic, off-the-shelf invaria
SeekingAlpha · Aug 13, 2026
MiNK Therapeutics, Inc. (INKT) Presents at 2026 Military Health System Research Symposium - Slideshow
2026-08-13. The following slide deck was published by MiNK Therapeutics, Inc.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
